Evoke Pharma, Inc.
EVOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 97.8% | 106.5% | 55% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.5% | 96.1% | 85.2% | 79.7% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 3.4% | -138.1% | -307.9% | -496.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -52.2% | -150.4% | -327.8% | -527.7% |
| EPS Diluted | -2.81 | -27.97 | -31.16 | -40.4 |
| % Growth | 90% | 10.2% | 22.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |